40 results about "Dysthymic Disorder" patented technology

The invention provides a method for constructing a mood disorder assessment model based on hierarchical multilevel gating, which comprises the following steps: acquiring electroencephalogram signals of a plurality of testees, labeling labels, and constructing a first training sample set; training by using the first training sample set to obtain time sequence dynamic graph network feature extraction models corresponding to the multiple electroencephalogram parameter combinations and related time sequence dynamic graph network features; constructing a second training sample set by using the first training sample set and the time sequence dynamic graph network features, and training a hierarchical multilevel gating model; and obtaining a mood disorder assessment model based on the time sequence dynamic graph network feature extraction model and the hierarchical multi-level gating model corresponding to each electroencephalogram parameter combination. According to the method, the problem that the assessment accuracy is limited due to the fact that a mood disorder assessment model in the prior art does not consider the correlation between different parameter combinations among the brain region, the frequency band and the observation time length and the task and does not perform hierarchical screening on different parameter brain networks based on the task correlation is solved.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

The invention provides a mood disorder assessment system based on multi-level feature fusion, and the system comprises a data collection unit which is used for collecting electroencephalogram signals of a plurality of brain regions of a to-be-assessed patient; the electroencephalogram feature extraction unit is used for extracting electroencephalogram features corresponding to the electroencephalogram signals of the brain regions; the multi-level feature extraction unit is constructed on the basis of the symptom features of the multiple testees and the corresponding electroencephalogram features, and is used for performing multi-level electroencephalogram feature latent variable extraction on the electroencephalogram features of the brain regions of the patient to be evaluated to obtain multi-level electroencephalogram feature latent variables; and the feature fusion and classification unit is used for carrying out classification prediction based on the electroencephalogram feature latent variables to obtain a mood disorder assessment result of the patient to be assessed. The method solves the problem that a mood disorder assessment system in the prior art adopts a single feature extraction and learning strategy and has no constraint of symptom information, so that the recognition capability of a model for mood disorders of different functional abnormality types is limited.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as Parkinson's disease, psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present invention provides a method for controlling mood and anxiety disorders in TMS therapy based on emotion induction, including the following steps: conducting a clinical assessment of the patient's mental health before treatment; performing a brain magnetic resonance imaging (MRI) examination of the patient under emotion induction; prioritizing selected individualized targets based on the patient's clinical assessment and the degree of abnormal brain function activity under emotion induction; formulating a TMS treatment plan under emotion induction based on the target priority ranking; conducting a short-term treatment evaluation and utilizing an efficacy prediction model to perform a long-term prediction of the remaining treatment trajectory; and after completion of treatment, feeding the treatment trajectory back to a local database and conducting a post-treatment clinical evaluation. The present invention also relates to a corresponding device, processor, and storage medium. Using the method, device, processor, and storage medium of the present invention, the control differences of patients under different scenarios can be effectively displayed using a scenario stimulus library and scenario brain function imaging.

The present disclosure provides a crystalline form of enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating mood disorders, neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using a crystalline form of enantiopure deuterium-enriched bupropion.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI). vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention discloses a multi-mode mood disorder classification method based on fMRI and voice, and the method mainly aims at constructing an fMRI and voice interaction fusion network framework which is composed of three stages of network structures, namely, a double-branch feature extraction network used for carrying out the feature extraction of voice data and fMRI signals, and a multi-branch feature extraction network used for carrying out the feature extraction of the voice data and the fMRI signals. The feature interaction fusion network is used for converting the multi-modal features into fusion features containing key information of data of each modal, and the full connection layer network is used for mapping the fusion features to category probabilities. A brain network topological structure and voice features which are related to mood disorder classification tasks and have high discrimination capability are effectively extracted from fMRI and voice data; therefore, cross-modal causal association between the fMRI and the voice data is effectively mined, and high-precision and interpretable mood obstacle recognition and classification are realized.

The present invention relates to a biomarker for distinguishing mood disorder-type psychiatric diseases and schizophrenia, and uses thereof. Based on a biomarker composition for mood disorder-type psychiatric diseases and schizophrenia comprising the serum proteins including leptin, tumor necrosis factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), and brain-derived neurotrophic factor (BDNF), the present invention describes a composition for distinguishing mood disorder-type psychiatric diseases and schizophrenia, comprising reagents for measuring the expression levels of the five biomarker proteins, and a method for providing information for distinguishing between mood disorder-type psychiatric diseases and schizophrenia, using same.

The present invention relates to a treatment method for TMS treatment of mood disorders and anxiety disorders based on emotion induction, comprising: conducting a clinical assessment of the patient's mental health before treatment; performing a brain magnetic resonance imaging (MRI) examination of the patient under emotion induction; prioritizing selected individualized targets based on the patient's clinical assessment and the degree of abnormal brain functional activity under emotion induction; formulating a TMS treatment plan under emotion induction scenarios based on the target priority ranking; conducting a short-term treatment evaluation and utilizing an efficacy prediction model to perform a long-term prediction of the remaining treatment trajectory; and after the treatment is completed, feeding the treatment trajectory back to a local database and conducting a post-treatment clinical evaluation. The present invention also relates to a corresponding device, processor, and storage medium. Using the method, device, processor, and storage medium of the present invention, the control differences of patients under different scenarios can be effectively displayed through a scenario stimulus library and scenario brain function imaging.

The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as agonists or antagonists of the serotonin (5-HT2A) receptor, preferably non-hallucinogenic biased agonists at the serotonin (5-HT2A) receptor, such as having agonism biased towards the beta-arrestin signaling pathway. Such compounds are useful for the treatment of mood disorders, general anxiety, social anxiety, depression, and other neuropsychiatric diseases.

The application provides a kind of construction method of mood disorder evaluation model based on hierarchical multi-level gating, comprising: obtaining the electroencephalogram of a plurality of subjects, labeling label, constructing first training sample set;Using first training sample set for training, obtaining a plurality of electroencephalogram parameter combinations respectively corresponding time sequence dynamic graph network feature extraction model and related time sequence dynamic graph network features;Using first training sample set, time sequence dynamic graph network features to construct second training sample set, train hierarchical multi-level gating model;Based on the time sequence dynamic graph network feature extraction model corresponding to each electroencephalogram parameter combination and hierarchical multi-level gating model, obtain mood disorder evaluation model.The application solves the problem that the mood disorder evaluation model in the prior art does not consider the correlation between different parameter combinations and tasks among brain regions, frequency bands and observation time lengths, does not perform hierarchical screening of different parameter brain networks based on task correlation, resulting in limited evaluation accuracy.

The present disclosure provides a crystalline form of enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating mood disorders, neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using a crystalline form of enantiopure deuterium-enriched bupropion.

Described herein, in part, are dosage forms and compositions useful for the prevention and / or treatment of diseases or conditions associated with aberrant T-type calcium channel function, such as epilepsy and epileptic syndromes (e.g., absent seizures, teenager myospastic epilepsy or genetic epilepsy), tremor (e.g., epilepsy seizures, spasmodic epilepsy, or hereditary epilepsy), or tremor (e.g., epilepsy seizures). Idiopathic tremor (e.g., idiopathic tremor) and psychiatric disorders (e.g., mood disorders (e.g., severe depressive disorder)). The invention also includes methods for modulating the function of T-type calcium channels.

The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as selective agonists or antagonists serotonin (5-HT2A) receptor, preferably non-hallucinogenic biased agonists or antagonists at the serotonin (5-HT2A) receptor, such as having agonism biased towards the beta-arrestin signaling pathway, or as serotonin (5-HT2A) receptor antagonists. Such compounds are useful for the treatment of mood disorders, general anxiety, social anxiety, depression, anhedonia, and other neuropsychiatric diseases.

The present invention relates to Bifidobacterium longum strain CECT 30763, to cellular components, metabolites and secreted molecules thereof, to compositions comprising the products mentioned above, and to their use in the prevention or treatment of mood disorders (e.g., depression and anxiety), cardiovascular metabolic disorders or liver disorders presented alone or as a co-disease.

The invention provides compounds of the formula (I):wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

The present disclosure provides ergoline compounds and their use in the treatment of mood disorders. Pharmaceutical compositions and methods of making various ergoline compounds are provided.

The present invention is drawn to a method for in vitro diagnosing mood disorders particularly depression disorders, more preferably major depressive episode (DEP) in a human patient from a biological sample of said patient, using at least one or a combination of particular A to I editing RNA biomarkers associated to a specific depression score and algorithm. The present invention is also directed to a method for monitoring treatment for mood disorders in a human subject, preferably for monitoring depression, said method implementing the method for diagnosing mood disorders of the present invention. Kit for determining whether a patient presents a mood disorder, preferably depression disorder, more preferably DEP, is also comprised in the present invention.

The present invention provides a multi-parameter fusion mood disorder assessment system based on a time-series dynamic graph network, comprising: a data acquisition unit for collecting EEG signals of patients to be assessed; an EEG encoding unit for extracting EEG features corresponding to the EEG signals; a time-series dynamic graph network feature extraction unit for constructing a time-series dynamic graph network sequence related to multiple EEG parameter combinations and extracting related time-series dynamic graph network features; a demographic information encoding unit for encoding demographic information to obtain demographic encoding features; and a hierarchical multi-level gating unit for predicting mood disorder assessment results based on the time-series dynamic graph network features corresponding to the EEG parameter combinations obtained by screening the obtained time-series dynamic graph network features of the sequentially arranged multi-level gating layers. The present invention solves the problem that the mood disorder assessment system in the prior art does not consider the correlation between the multi-parameter combination and the task, and does not screen the brain network model through hierarchical gating, resulting in limited assessment accuracy.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof, wherein - - - - -, R1, R2, R3a, R3b, R4a , R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

Compositions consist essentially of trigonelline or consist of trigonelline. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to a mammal to treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The mitochondria-related disease or condition is selected from the group consisting of deleterious effects of aging, stress (e.g., oxidative stress), obesity, overweight, reduced metabolic rate, metabolic syndrome, diabetes mellitus, complications from diabetes, hyperlipidemia, neurodegenerative disease, cognitive disorder, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal death or dysfunction, chronic kidney disease, kidney failure, trauma, infection, cancer, hearing loss, macular degeneration, myopathies and dystrophies, and combinations thereof.

Provided herein are methods for treating psychiatric disorders by gene therapy (e.g. AAV-directed gene therapy) to deliver and express the human SP4 gene in neuronal cells. Treatable psychiatric disorders include schizophrenia, anxiety, obsessive compulsive disorder, or mood disorder.

The application provides a mood disorder evaluation model construction method and equipment based on electroencephalogram and symptom-oriented fusion. The method comprises the following steps: obtaining multiple mood disorder related symptom characteristics of multiple subjects; collecting electroencephalogram characteristics of multiple brain regions of each subject to construct a first training sample set; based on the first training sample set, a multi-level symptom-oriented feature extraction module is constructed, and multiple levels of electroencephalogram characteristic latent variables oriented by symptoms are obtained; based on the electroencephalogram characteristic latent variables of each level, the corresponding mood disorder diagnosis label is labeled, and then the feature fusion module and the classification module are iteratively trained; based on the multi-level symptom-oriented feature extraction module, the feature fusion module and the classification module, a mood disorder evaluation model is obtained. The application solves the problem that in the prior art, a single feature extraction and learning strategy is adopted, and there is no constraint of symptom information, resulting in limited recognition ability of the model for mood disorders of different functional abnormal types.

Described herein, in part, are dosage forms and compositions useful for the prevention and / or treatment of diseases or conditions associated with aberrant T-type calcium channel function, such as epilepsy and epileptic syndromes (e.g., absent seizures, teenager myospastic epilepsy or genetic epilepsy), tremor (e.g., epilepsy seizures, spasmodic epilepsy, or hereditary epilepsy), or tremor (e.g., epilepsy seizures). Idiopathic tremor (e.g., idiopathic tremor) and psychiatric disorders (e.g., mood disorders (e.g., severe depressive disorder)). The invention also includes methods for modulating the function of T-type calcium channels.

This article discloses a lipid prodrug of bromo-lysergic acid diethylamide (2-bromo-LSD) (2-bromo-lysergic acid diethylamide), which achieves improved pharmacokinetic properties and allows for easier long-term administration to patients. The disclosed lipid prodrug is indicated for the treatment of cluster headaches and mood disorders in human subjects.